Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

cfMeDIP-seq Provides Opportunity for Early Cancer Detection, Classification, and Monitoring

May 18th 2021

Cell-free methylated DNA immunoprecipitation-sequencing uses plasma cell-free methylomes to detect and classify several types of cancer early on, and provides the opportunity to monitor tumors for response to treatment in noninvasive way.

Dr. Rini on the Results of an Exploratory Analysis of the IMmotion151 Trial in mRCC

May 17th 2021

Brian I. Rini, MD, discusses the results of an exploratory analysis of the phase 3 IMmotion151 trial in metastatic renal cell carcinoma.

Dr. Hammers on the Importance of Assessing Quality of Life in RCC

May 12th 2021

Hans Hammers, MD, PhD, discusses the importance of assessing quality of life in renal cell carcinoma.

Tivozanib Boosts RCC Treatment Portfolio

May 10th 2021

Daniel J. George, MD, discussed how tivozanib differs from other TKIs and its potential to fill an unmet need in the treatment of patients with renal cell carcinoma.

FDA Grants Priority Review to Pembrolizumab/Lenvatinib for Advanced RCC and Endometrial Carcinoma

May 6th 2021

The FDA has granted priority review to applications that are seeking 2 approvals of pembrolizumab in combination with lenvatinib in advanced renal cell carcinoma and advanced endometrial carcinoma.

Tivozanib Approval Adds to the Armamentarium in Relapsed/Refractory Advanced RCC

May 2nd 2021

Brian I. Rini, MD, discusses the unique characteristics of tivozanib, how the FDA approval of the VEGF inhibitor is poised to further the advanced RCC paradigm, and the potential future utility of the agent.

Dr. Osipov on the Role of Combination Immunotherapy Across Multiple Tumor Types

April 30th 2021

Arsen Osipov, MD, discusses the role of combination immunotherapy across multiple tumor types.

Hutson Dives Into Controversial Depths: When Is Nephrectomy Appropriate in RCC?

April 28th 2021

In patients with renal cell carcinoma, factors that determine whether a partial or full nephrectomy should be performed include tumor location and size, but efforts should be made to perform partial nephrectomies whenever possible to preserve kidney function.

FDA Panel Endorses Atezolizumab for Frontline Metastatic Urothelial Cancer

April 28th 2021

In a 10 to 1 vote, the FDA’s Oncologic Drugs Advisory Committee voted to support the accelerated approval of atezolizumab for the frontline treatment of patients with cisplatin-ineligible locally advanced or metastatic urothelial carcinoma.

ODAC Votes in Favor of Pembrolizumab Approval in Frontline Metastatic Urothelial Cancer

April 28th 2021

In a 5 to 3 vote, the FDA’s Oncologic Drugs Advisory Committee voted to uphold the accelerated approval of pembrolizumab for the frontline treatment of patients with cisplatin-ineligible and carboplatin-ineligible locally advanced or metastatic urothelial carcinoma.

Dr. Devitt on Utilizing PD-L1 in Biomarker-Guided Therapies in Bladder Cancer

April 28th 2021

Michael Devitt, MD, discusses utilizing PD-L1 status in biomarker-guided therapies for patients with bladder cancer.

2021 GU Cancers Symposium Unveils Exciting Approaches in Bladder Cancer

April 27th 2021

The CheckMate 274 trial may have captured attention during the 2021 Genitourinary Cancers Symposium, but immunotherapy is not the only promising approach under study in urothelial carcinoma.

Dr. Rini on the Mechanism of Action of Tivozanib in Relapsed/Refractory RCC

April 26th 2021

Brian I. Rini, MD, discusses the mechanism of action of tivozanib in relapsed/refractory renal cell carcinoma.

Dr. Choudhury on Future Research Directions for Pembrolizumab/Radium-223 in mCRPC

April 26th 2021

Atish D. Choudhury, MD, PhD, discusses future research directions for the combination of pembrolizumab and radium-223 dichloride in patients with metastatic castration-resistant prostate cancer.

ODAC Hearings on 6 Immunotherapy Indications Set to Begin

April 26th 2021

The FDA’s Oncologic Drugs Advisory Committee is poised to move forward this week with a public review of 6 indications for immune checkpoint inhibitors granted under the agency’s accelerated approval process that later failed to reach thresholds for statistical significance for key end points in confirmatory clinical trials.

Nivolumab Alone, Plus Ipilimumab Being Tested in Early-Stage, High-Risk RCC

April 21st 2021

The safety and efficacy of nivolumab, both as a single agent and in combination with ipilimumab, is under investigation in patients with early-stage, high-risk renal cell carcinoma following radical or partial nephrectomy in the phase 3 CheckMate-914 trial.

Entering an Era of Immunotherapy-Based Combinations for Metastatic RCC

April 18th 2021

The frontline treatment landscape of renal cell carcinoma is exploding with immunotherapy-based options.

Hutson Highlights Treatment Journey in Clear Cell RCC Case

April 16th 2021

When considering which frontline option to administer to a patient with renal cell carcinoma, it is important to first understand which risk group they belong to.

NK Cell–Targeting Strategies Come Into Their Own

April 16th 2021

Although anticancer therapies that leverage T cells have commanded the most attention in the immuno-oncology era of the past decade, strategies based on natural killer cells have recently emerged as attractive approaches.

Pal Previews Potential Second-line and Beyond Options in RCC

April 15th 2021

Sumanta K. Pal, MD, details ongoing research efforts dedicated to providing additional therapeutic options for patients with RCC in the second-line setting and beyond.